Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 23.e9-23.e13

  Shuch, Brian ^a   Hofmann, Jonathan N ^a   Merino, Maria J ^a   Nix, Jeffrey W ^a   Vourganti, Srinivas ^a   Linehan, W Marston ^a   Schwartz, Kendra ^b   Ruterbusch, Julie J ^b   Colt, Joanne S ^a   Purdue, Mark P ^a   Chow, Wong Ho ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Accuracy; Concordance; Histology; Pathology; RCC; SEER

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER REGISTRY; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; ICD-O-3; KIDNEY CARCINOMA; KIDNEY PAPILLA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NEPHRECTOMY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; CARCINOMA, RENAL CELL; ILLINOIS; KIDNEY NEOPLASMS; MICHIGAN; PATHOLOGY; REPRODUCIBILITY;

ADULT; AGED; CARCINOMA, RENAL CELL; CHICAGO; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MICHIGAN; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SEER PROGRAM; SENSITIVITY AND SPECIFICITY;

EID: 84890798522     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.08.011     Document Type: Article

References (17)

1. Institute, U. N. I. o. H. N. C. Surveillance epidemiologic and end result: quality improvement tools. Bethesda, MD; 2011.
2. Bull A.D., Biffin A.H., Mella J., et al. Colorectal cancer pathology reporting: a regional audit. J Clin Pathol 1997, 50:138.
3. Shuch B., Pantuck A.J., Pouliot F., et al. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance. BJU Int 2011, 108:343.
4. Field R.W., Smith B.J., Platz C.E., et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 2004, 96:1105.
5. Colt J.S., Schwartz K., Graubard B.I., et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 2011, 22:797.
6. Storkel S., Eble J.N., Adlakha K., et al. Classification of renal cell carcinoma: Workgroup no. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80:987.
7. Chow W.H., Devesa S.S., Warren J.L., et al. Rising incidence of renal cell cancer in the United States. J Am Med Assoc 1999, 281:1628.
8. Hollingsworth J.M., Miller D.C., Daignault S., et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006, 98:1331.
9. Rothman J., Egleston B., Wong Y.N., et al. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol 2009, 181:29.
10. Didwaniya N, Edmonds RJ, Fang X, et al. Survival outcomes in metastatic renal carcinoma based on histological subtypes: SEER database analysis. J Clin Oncol 2011;29(suppl. 7; abstr 381).
11. Keegan K.A., Schupp C.W., Chamie K., et al. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol 2012.
12. Liu L., Qian J., Singh H., et al. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med 2007, 131:1290.
13. Gobbo S., Eble J.N., Grignon D.J., et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol 2008, 32:1239.
14. Kovacs G., Wilkens L., Papp T., et al. Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. J Natl Cancer Inst 1989, 81:527.
15. Finley D.S., Shuch B., Said J.W., et al. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. J Urol 2011, 186:2168.
16. Linehan W.M. The genetic basis of kidney cancer: implications for management and use of targeted therapeutic approaches. Eur Urol 2012.
17. Staradub V.L., Messenger K.A., Hao N., et al. Changes in breast cancer therapy because of pathology second opinions. Ann Surg Oncol 2002, 9:982.